Lupin Contributes Rs 21 crores in battle against COVID-19

Mumbai: Lupin Limited has announced a contribution of INR 21 crores for relief efforts directed towards mitigating the COVID-19 crisis. Lupin's Global Giving Program comprises of three separate contributions made by its employees, the Company and the promoter family.

Lupin's employees have contributed generously by giving two days of their individual salaries, together contributing a sum of INR 5.5 crores to the Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund). Lupin has matched an equal sum of INR 5.5 crores for direct initiatives that the company will implement to support overburdened national and state healthcare systems through the donation of personal protective equipment, medicines and providing meals for front-line workers and the needy.

In addition, the promoter Desh Bandhu Gupta family has committed a sum of INR 10 crores for other direct impact initiatives in India and elsewhere in the world to supplement Lupin's relief efforts to tackle the COVID-19 crisis.

Commenting on this, Mr Nilesh Gupta, Managing Director, Lupin said, "We commend the Central and State governments in India and other authorities globally for taking proactive measures to control the spread of the coronavirus. As one of the leading pharmaceutical companies globally, Lupin remains committed to ensure uninterrupted supply of medicines across India and global markets while ensuring the safety of our personnel involved. We are grateful for this opportunity to support those who are at the front-line of this battle against COVID-19."

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. The Company invests 9.6 % of its revenues on research and development.

Read also: Lupin Gets USFDA EIR For Nagpur Facility